Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
45.46
-0.14 (-0.31%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Exact Sciences Employees
Exact Sciences had 7,000 employees as of December 31, 2024. The number of employees increased by 400 or 6.06% compared to the previous year.
Employees
7,000
Change (1Y)
400
Growth (1Y)
6.06%
Revenue / Employee
$394,124
Profits / Employee
-$146,980
Market Cap
8.44B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7,000 | 400 | 6.06% |
Dec 31, 2023 | 6,600 | 200 | 3.13% |
Dec 31, 2022 | 6,400 | -100 | -1.54% |
Dec 31, 2021 | 6,500 | 1,500 | 30.00% |
Dec 31, 2020 | 5,000 | 890 | 21.65% |
Dec 31, 2019 | 4,110 | 2,133 | 107.89% |
Dec 31, 2018 | 1,977 | 709 | 55.91% |
Dec 31, 2017 | 1,268 | 532 | 72.28% |
Dec 31, 2016 | 736 | 59 | 8.71% |
Dec 31, 2015 | 677 | 441 | 186.86% |
Dec 31, 2014 | 236 | 134 | 131.37% |
Dec 31, 2013 | 102 | 15 | 17.24% |
Dec 31, 2012 | 87 | 26 | 42.62% |
Dec 31, 2011 | 61 | 26 | 74.29% |
Dec 31, 2010 | 35 | 16 | 84.21% |
Dec 31, 2009 | 19 | 15 | 375.00% |
Dec 31, 2008 | 4 | -10 | -71.43% |
Dec 31, 2007 | 14 | -8 | -36.36% |
Dec 31, 2006 | 22 | -27 | -55.10% |
Dec 31, 2005 | 49 | -22 | -30.99% |
Dec 31, 2004 | 71 | -11 | -13.41% |
Dec 31, 2003 | 82 | 7 | 9.33% |
Dec 31, 2002 | 75 | 7 | 10.29% |
Dec 31, 2001 | 68 | 24 | 54.55% |
Dec 31, 2000 | 44 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
EXAS News
- 5 days ago - Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test - Business Wire
- 13 days ago - JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups - Business Wire
- 26 days ago - Exact Sciences Schedules First Quarter 2025 Earnings Call - Business Wire
- 27 days ago - Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening - Business Wire
- 6 weeks ago - Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner - Business Wire
- 6 weeks ago - New Data Highlight the Positive Impact of Exact Sciences' Oncotype DX® Test on Patient Care and Healthcare Efficiency - Business Wire
- 2 months ago - Exact Sciences to Participate in March Investor Conferences - Business Wire
- 2 months ago - Exact Sciences: A Strong Q4 Reveals Signs Of A Potential Inflection Point - Seeking Alpha